It is frustrating that the company wasted resources to file for BTD for TNBC and set expectations for investors that BTD was realistic at this time. The company should understand competition and know that our submitted data was not up to the standards of BTD.
In addition, I wonder why it took so much time to hear back from the FDA as they could quickly see that the data was not superior to a drug recently approved.
A frustrating start to a year following an incredibly frustrating 2021
Disappointing
IMO